Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
10 sept. 2021 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Decibel-full color-CMYK.png
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
09 sept. 2021 07h30 HE | Decibel Therapeutics, Inc.
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
VectivBio_Logo_RGB_Color.png
VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
08 sept. 2021 07h15 HE | VectivBio AG
BASEL, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
07 sept. 2021 08h00 HE | Travere Therapeutics, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug...
VectivBio_Logo_RGB_Color.png
VectivBio to Acquire Comet Therapeutics and Host R&D Day
31 août 2021 07h00 HE | VectivBio AG
- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -- VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE...
logo_ProQR-150x150.png
ProQR Announces Second Quarter 2021 Operating and Financial Results
05 août 2021 07h00 HE | ProQR Therapeutics N.V.
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis...
Saniona får särläkemedelsklassning av FDA för Tesomet mot hypotalamisk fetma
26 juil. 2021 02h00 HE | Saniona AB
PRESSMEDDELANDE 26 juli 2021 Tesomet är det första och enda prövningsläkemedlet för behandling av hypotalamisk fetma som erhållit särläkemedelsklassning Saniona (OMX: SANION), ett...
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity
26 juil. 2021 02h00 HE | Saniona AB
PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage...
Parexel Master Logo_CMYK.png
Parexel Announces Innovative Partnership with Rare Disease Foundation in China
22 juil. 2021 09h00 HE | Parexel International LLC
BOSTON and DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance...
Imara-Logo-Color-RGB.jpg
Imara Announces Launch of Proposed Public Offering
13 juil. 2021 16h01 HE | Imara, Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...